FOCUS ON TYPE 2 DIABETES (VASC-120)

Disclosure(s):

Hertzel Gerstein, MD MSc: Abbott: Consultant/Advisory Board (Ongoing); AstraZeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Terminated, December 31, 2022), Speaker/Honoraria (Terminated, December 31, 2022); DKSH: Speaker/Honoraria (Terminated, June 30, 2022); Hanmi: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Jiangsu - Hansen: Speaker/Honoraria (Terminated, June 30, 2023); Kowa: Consultant/Advisory Board (Terminated, December 31, 2022); Lilly: Consultant/Advisory Board (Ongoing), Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Speaker/Honoraria (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Zuellig: Speaker/Honoraria (Terminated, May 31, 2023)